Pronutria Biosciences develops first-in-class medicines that use disease-specific amino acid compositions to restore cellular homeostasis and regenerate function. The company designs oral biologics derived from the food proteome and applies a systems pharmacology approach to select therapeutic amino-acid combinations. Its proprietary platform evaluates over one billion potential candidates and has advanced clinical-stage medicines in muscle, neurodegenerative and liver conditions. Pronutria is developing both therapeutics and nutritional supplements and says its platform can address patients across more than 2,000 diseases where amino acids play a central role. The company plans to expand existing muscle, neurological and liver disease programs as it advances lead candidates toward the clinic. Pronutria is based in Cambridge, MA and was founded within VentureLabs at Flagship Ventures. Pronutria is pioneering a novel class of amino acid–based products—termed amino acid biologics—targeting biology previously inaccessible with precise modulation of amino acid pathways. The company is clinical-stage and says it has amassed promising preclinical and clinical data across a pipeline of candidates. Its R&D programs span nutritional and therapeutic areas including muscle, metabolic, neurological and liver disorders, plus inborn errors of metabolism. Management states the technology leverages advanced knowledge of amino acid imbalances to address conditions with few or no current options. Pronutria was founded by Flagship VentureLabs and is based in Cambridge, MA. The company recently completed a $39 million Series C financing, strengthening its financial position to aggressively advance multiple programs.

Total raised

$105M

Funding rounds

4

Latest round

Equity

Latest activity

Feb 2016